Chapter 6 │ Page 214 18. Khalili, M., et al., Non-Thermal Plasma Induced Immunogenic Cell Death in a Colorectal and Pancreatic Cancer Murine Model. Journal of the American College of Surgeons, 2018. 227(4, Supplement 2): p. e217. 19. Van Loenhout, J., et al. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. Cells, 2021. 10, DOI: 10.3390/cells10112936. 20. Živanić, M., et al., Injectable Plasma-Treated Alginate Hydrogel for Oxidative Stress Delivery to Induce Immunogenic Cell Death in Osteosarcoma. Advanced Functional Materials, 2024. 34(14): p. 2312005. 21. Ghosh, S., Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 2019. 88: p. 102925. 22. Ranasinghe, R., M.L. Mathai, and A. Zulli, Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon, 2022. 8(9): p. e10608. 23. Bezu, L., et al., Combinatorial strategies for the induction of immunogenic cell death. Frontiers in immunology, 2015. 6: p. 187-187. 24. Fucikova, J., et al., Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death & Disease, 2020. 11(11): p. 1013. 25. Park, S.J., et al., Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol, 2019. 95: p. 127-135. 26. Tran, L., et al., Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer immunology research, 2017. 5(12): p. 1141-1151. 27. Martins, I., et al., Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene, 2011. 30(10): p. 1147-58. 28. Lin, L., et al., Non - thermal plasma inhibits tumor growth and proliferation and enhances the sensitivity to radiation in vitro and in vivo. Oncol Rep, 2018. 40(6): p. 3405-3415. 29. Brullé, L., et al., E ects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma Model. PLOS ONE, 2012. 7(12): p. e52653. 30. Lafontaine, J., et al., Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines. Cancers (Basel), 2020. 12(2). 31. Wang, H.Q., et al., Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma. J Clin Med, 2023. 12(6). 32. Cappell, K.M. and J.N. Kochenderfer, Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews Clinical Oncology, 2023. 20(6): p. 359371. 33. Lee, K.W., J.W.P. Yam, and X. Mao, Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 2023. 12(17). 34. Yu, J., et al., Research progress on dendritic cell vaccines in cancer immunotherapy. Experimental Hematology & Oncology, 2022. 11(1): p. 3. 35. Yi, M., et al., Exploiting innate immunity for cancer immunotherapy. Molecular Cancer, 2023. 22(1): p. 187. 36. Page, A., et al., Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & Molecular Immunology, 2024. 21(4): p. 315-331.
RkJQdWJsaXNoZXIy MTk4NDMw